D.Sc., Professor, Genetics and Genome Sciences, University of Connecticut
Recognizing that prenatal screening and diagnosis is being radically changed by the discovery of cell-free DNA in maternal plasma, Dr Benn has been focused on the technical, practical, economic and ethical issues associated with the introduction of this technology. He chairs the International Society for Prenatal Diagnosis’ Position Statement Committee for Aneuploidy Screening. He is a Professor of Genetics and Genome Sciences at the University of Connecticut and has lectured and published extensively in the area of prenatal screening and diagnosis. Dr. Benn received his undergraduate and Doctor of Science degree from the University of St. Andrews, Scotland. He completed his PhD at the University of Birmingham, England in Cancer Studies and received post-doctoral training at Department of Human Genetics, University of Pennsylvania.
Non-invasive Testing for Low-risk Women
Analysis of cell-free DNA in maternal plasma is, by far, the most effective method to screen for fetal chromosome abnormalities. However, the testing is not fully diagnostic and the positive predictive value is expected to be somewhat lower for women with a low a priori risk. Recent clinical trials support testing for all women.